Good evening :)
$
₹
Organon & Co

Organon & Co

OGN

NYSE
Asset Logo

Organon & Co

OGN

NYSE
$13.690.10% (+0.01)
$
₹
$13.690.10% (+0.01)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - General

Mid Cap

With a market cap of $3.6B the stock is ranked 1723

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

17.53
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.57
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.78
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

3.40%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

0.58%

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 7 analysts' reports

Buy
2 analysts
Hold
3 analysts
Sell
2 analysts

Analysts expect a -17.76% price downside over the next year

Current Price$13.69
Target Price$11.25

Company Profile

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Peers

Peers

Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
38.75
38.75
1Y Return
54.52%
54.52%
Buy Reco %
77.41
77.41
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
31.35
31.35
1Y Return
55.66%
55.66%
Buy Reco %
45.83
45.83
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
117.49
117.49
1Y Return
85.94%
85.94%
Buy Reco %
57.69
57.69
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
21.17
21.17
1Y Return
14.28%
14.28%
Buy Reco %
15.38
15.38
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
24.86
24.86
1Y Return
7.19%
7.19%
Buy Reco %
90.00
90.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Organon & Co 17.533.57-
Eli Lilly and Company38.7530.331.13
Johnson & Johnson31.357.652.83

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

1.6
0.1
1.5
-0.2
1.4
0.1
1.5
0.1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue1.621.601.581.591.511.591.601.501.461.55
Net Income0.200.190.350.100.080.140.16-0.200.140.10
Net Profit Margin12.39%12.13%22.69%6.84%5.75%9.09%9.98%-13.60%10%6.93%
See CostsAll values in $ Billion

Frequently asked questions

  1. Organon & Co (OGN) share price today is $13.69 as of September 22, 2026 at 10:25 PM IST. The stock touched a day high of $13.69 and a day low of $13.68.

  2. Organon & Co stock trades on NYSE under the ticker symbol OGN.

  3. Organon & Co's market capitalization is $3.59B as of September 22, 2026 at 10:25 PM IST.

  4. Organon & Co's price-to-earnings (P/E) ratio is 17.53 as of September 22, 2026.

  5. Organon & Co's price-to-book (P/B) ratio is 3.57 as of September 22, 2026.

  6. Yes, Organon & Co pays a dividend, with a current dividend yield of 0.58%.

  7. Yes, You can buy Organon & Co shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Organon & Co shares in three steps: 1. Search Organon & Co on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Organon & Co trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Organon & Co (OGN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.7301 shares at the current price of $13.69.

Loading...